Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05826535 · ClinicalTrials.gov registry record · Phase 1
Study of LYL314 in Aggressive Large B-Cell Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma and Large B-cell Lymphoma, sponsored by Lyell Immunopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT05826535 is a Phase 1 study of Non-Hodgkin Lymphoma and Large B-cell Lymphoma that is actively recruiting participants, run by Lyell Immunopharma. The registered enrollment target is 270 participants, above the 149-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05826535, a Phase 1 study of Non-Hodgkin Lymphoma and Large B-cell Lymphoma, is actively recruiting participants, sponsored by Lyell Immunopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG LYL314
Study Locations (20)
California
- University of California-Irvine Medical Center - Irvine
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles (UCLA) Medical Center - Los Angeles
- Scripps Clinic - San Diego
Pennsylvania
- Lehigh Valley Topper Cancer Center Institute - Allentown
- Thomas Jefferson University - Philadelphia
- West Penn Hospital - Pittsburgh
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Montefiore Medical Center - The Bronx
Ohio
- University of Cincinnati (UC) Physicians Company, LLC - Cincinnati
- Cleveland Clinic - Cleveland
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Augusta University Medical Center - Augusta
Indiana
- Indiana Blood and Marrow Transplantation - Indianapolis
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2023-05-09 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05826535
The ClinicalTrials.gov registry entry for NCT05826535 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (81% higher). The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05826535 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Pennsylvania, New York.
Frequently Asked Questions
What is clinical trial NCT05826535 about?
NCT05826535 is a clinical study titled "Study of LYL314 in Aggressive Large B-Cell Lymphoma". This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
What is the current status of trial NCT05826535?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2023-05-09. Estimated completion is 2031-06-30.
What conditions does trial NCT05826535 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05826535?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), LYL314 (DRUG).
Who is sponsoring clinical trial NCT05826535?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05826535 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.